Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn)  by Batelli, S. et al.
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OMACROAUTOPHAGY AND THE PROTEASOME ARE DIFFERENTLY
INVOLVED IN THE DEGRADATION OF ALPHA-SYNUCLEIN WILD
TYPE AND MUTATED A30P IN AN IN VITRO INDUCIBLE MODEL
PC12/TETON)
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Abstract—Many data suggest that alpha synuclein (-syn)
ggregation is involved in Parkinson’s disease (PD) neuro-
oxicity and is accelerated by the pathogenetic point muta-
ion A30P. The triplication of -syn gene has been linked to
early-onset familial PD, suggesting that the cellular dosage of
-syn is an important modulator of its toxicity. To verify this
oint, we developed an inducible model of -syn expression
(both wild type [WT] and mutated A30P) in rat PC12/TetOn
cells. At low expression level, both -syn(WT) and (A30P) did
ot aggregate, were not toxic, and displayed a protective
ction against oxidative stress triggered by hydrogen perox-
de (H2O2). By increasing -syn expression, its antioxidant
unction was no longer detectable as for the A30P form, but
gain no aggregation and cell death were present both for the
T and the mutated protein. To clarify why -syn did not
accumulate at high expression level, we inhibited macroau-
tophagy by 3-methyladenine (3-MA) and the proteasome by
MG132. In presence of 3-MA, -syn(WT) accumulated, A11
nti-oligomer antibody-positive aggregates were detectable,
nd cell toxicity was evident, while proteasome inhibition did
ot increase -syn(WT) accumulation. Macroautophagy or
proteasome inhibition slightly increased -syn(A30P) toxic-
ty, with no detectable aggregation. This model can provide
seful details about -syn function, aggregation, and degra-
ation pathways. © 2011 IBRO. Published by Elsevier Ltd.
ey words: alpha-synuclein, protein aggregation, macroau-
ophagy, proteasome, oxidative stress, Parkinson’s disease.
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the degeneration of the dopaminergic
neurons of the substantia nigra pars compacta. This event
correlates with a deficit of dopamine in the striatum that is
at the basis of PD clinical features, including bradykinesia,
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277.
E-mail address: diego.albani@marionegri.it (D. Albani).
Abbreviations: CMA, chaperone-mediated autophagy; DOXY, doxycy-
cline; FCS, fetal calf serum; HS, horse serum; LB, Lewy bodies; LDH,
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lactate dehydrogenase release to lactate dehydrogenase; LN, Lewy neu-
rites; PD, Parkinson’s disease; UPS, ubiquitin-proteasome system.
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Open access under CC BY-NC-ND resting tremor, rigidity, and postural instability (Fahn,
2003). From the neuropathologic point of view, PD is char-
acterized in almost all forms by proteinaceous intracyto-
plasmic inclusion bodies called Lewy bodies (LB) and by
the presence of abnormally shaped neurites named Lewy
neurites (LN) (Dauer and Przedborski, 2003). The etio-
pathogenesis of PD is probably multifactorial, including
both environmental and genetic factors (Di Monte, 2003;
Gasser, 2009; Warner and Schapira, 2003). Several genes
(-syn, parkin, UCH-L1, DJ-1, LRRK2, PINK-1, and
R4A2) have been linked to genetic cases of PD (Bekris et
l., 2010; Hashimoto et al., 2003; Giasson and Lee, 2003;
ookson, 2003). Alpha-syn is the principal component of
B and LN (Fahn, 2003), and three autosomal dominant
issense mutations (an Ala to Pro substitution at codon 30
A30P], an Ala to Thr substitution at codon 53 [A53T] and
Glu to Lys [E46K] at codon 46) have been linked to
amilial PD (Polymeropoulos et al., 1997; Krüger et al.,
998; Zarranz et al., 2004). The available data about -syn
physiological functions deal with presynaptic plasticity, do-
pamine trafficking and homeostasis, exocytotic vesicle in-
teraction, regulation of monoamine transporters, and chap-
erone-like activity (Burré et al., 2010; Scott et al., 2010;
Garcia-Reitböck et al., 2010; Lykkebo and Jensen, 2002;
Wersinger et al., 2003; Oaks and Sidhu, 2011; Osterova et
al., 1999). A30P and A53T mutations affect the ability of
-syn to modulate dopamine vesicle trafficking, modify its
nteraction with cellular membranes (Saha et al., 2004;
ensen et al., 1998), and increase its natural propensity to
ggregate (Anderson et al., 2010; Volles and Lansbury,
003; el-Agnaf and Irvine, 2002; Conway et al., 2000).
The description of a family with early-onset PD that
howed a triplication of a chromosomic region containing
-syn gene suggested that the cellular dosage of the pro-
ein is critical for PD etiopathogenesis (Singleton et al.,
003; Uversky and Eliezer, 2009). Moreover, many puta-
ive triggers of idiopathic PD (mitochondrial complex I in-
ibitors, environmental toxins, oxidative stress, or protea-
ome impairment) cause -syn modifications that are suf-
cient to alter its intracellular concentration, leading to
ggregation and related toxicity (Riedel et al., 2011; Este-
es et al., 2011; Xie et al., 2010; Sherer et al., 2003; Norris
t al., 2003; Ischiropoulos and Beckman, 2003). From the
ther side, the existence of a neuroprotective pathway
ediated by native -syn is supported by some evidenceJin et al., 2011; Lee et al., 2010; Jensen et al., 2003;
license.
dS. Batelli et al. / Neuroscience 195 (2011) 128–137 129Fig. 1. Development of an inducible -syn expression system in PC12 cells. (A) Representative Western blot showing human -syn-inducible
expression. PC12 cells were transfected with a tetracycline responsive plasmid (pBI-G) carrying human -syn(WT or A30P) full-length cDNAs as
escribed in methods. The dynamic range of -syn expression was tested by addition of the antibiotic doxycycline (doxy.) for 96 h to culture mediumin a dose ranging between 0.1 and 1 g/ml. The bar graph (right) is the densitometric analysis of three independent Western blot experiments, using
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S. Batelli et al. / Neuroscience 195 (2011) 128–137130Manning-Bog et al., 2003; Seo et al., 2002; Hashimoto et
al., 2002).
To investigate whether -syn level modulates its func-
ion, aggregation, and toxicity we have developed an in-
ucible model of -syn expression in rat PC12/TetOn cells,
comparing the WT form to the mutated A30P, too.
EXPERIMENTAL PROCEDURES
PC12/TetOn(-syn) cell lines
A commercial PC12/TetOn cell line was purchased from Clontech
(Palo Alto, CA, USA) (Rossi and Blau, 1998). To express
-syn(WT) the corresponding cDNA was amplified by mean of
apid amplification of cDNA ends - polymerase chain reaction
RACE-PCR) from a human brain cDNA bank and then cloned into
n expression vector (pRSET, Invitrogen, Carlsbad, CA, USA)
nd fully sequenced. This plasmid served as template for intro-
ucing the A30P mutation by a site-directed mutagenesis com-
ercial kit (Invitrogen). To produce the TetOn/pBI-G vectors,
-syn cDNA sequences were excised from pRSET plasmids using
he unique restriction enzymes NotI and SalI (Roche, Basel, Swit-
erland) and inserted into different pBI-G vectors, cut with the
ame restriction enzymes.
PC12/TetOn cells were cultured on disposable plasticware
oated with poly-D-lysine at 37 °C, 5% CO2 in RPMI 1640 medium
Invitrogen) supplemented with 10% tetracycline-free horse serum
HS), 5% fetal calf serum (FCS) (Sigma Aldrich, St. Louis, MO,
SA), 2 mM L-glutamine, 100UI/ml penicillin, and 100 mg/ml
treptomycin (Invitrogen) in humidified atmosphere. Alpha-sy-
uclein expression was induced by doxycycline addition (range:
.1–1 g/ml) directly into culture medium.
Cell viability and oxidative stress challenge
Cell viability was assessed by MTT colorimetric assay (conversion
of a soluble tetrazolium salt (3–[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide) into an insoluble formazan precipitate)
and confirmed by lactate dehydrogenase release (LDH) assay
performed according to the manufacturer’s instructions (BioRad
Laboratories, Hercules, CA, USA).
To challenge PC12/TetOn cells with oxidative stress, 100103
undifferentiated cells were seeded in a 96-well plate and incu-
bated overnight. Next day, a freshly prepared H2O2 dilution was
added (final concentration: 150 M), and cells were incubated for
72 h. At the end of the experiment, the number of viable cells was
estimated as previously described.
Thioflavin-T binding assay for amyloid aggregate
detection
For thioflavin-T staining, cells (about 50103) were cultured on
oly-D-lysine-coated glass coverslips and treated with H2O2, as
previously reported. Then, cells were fixed for 20 min with a 4%
paraformaldehyde/PBS solution, incubated 8 min with a 0.05%
thioflavin-T solution and washed twice with PBS. Thioflavin-T
reactivity was analyzed using a fluorescence microscope coupled
to a digital camera (Olympus Corporation, Tokyo, Japan).
-tubulin immunoreactivity as normalization standard. (B) Immunocyto
upper picture for each cell line is the basal expression in absence of do
8-h induction by 1 g/ml doxycycline (doxy) (magnification 10; bar
oxycycline induction (1 g/ml for 48 h) is also presented (right-Barover time. The bar graphs (right) represent the densitometric analysis of threeImmunoblotting
Cellular total protein extracts were lysed in Laemmli SDS-PAGE
1 sample buffer, subjected to SDS-PAGE electrophoresis, and
transferred to a nitrocellulose membrane (BioRad Laboratories).
The membrane was then incubated overnight with a primary an-
tibody diluted in 5% nonfat dry milk in PBS-T (PBS0.1% Tween-
20). After washing, the membrane was incubated for 1 h with a
secondary antibody conjugated to horseradish peroxidase (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA) diluted 1:5000 in 5%
nonfat dry milk in PBS-T. The membrane was finally subjected to
ECL detection technique (GE Healthcare, Chalfont St. Giles, UK).
Immunocytochemistry
Cells (50103) were cultured on poly-D-lysine-coated chamber
slides and fixed for 20 min with 4% paraformaldehyde/PBS solu-
tion. The fixed cells were permeabilized using 0.5% Triton-X 100,
0.2% FCS in PBS for 5 min and incubated overnight with a primary
antibody diluted 1:100 in PBS with 1% HS. After washing, an
FITC-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) diluted 1:200 in PBS with 1%
HS was added for 30 min, and cells were analyzed by a fluores-
cence microscope coupled to a digital camera (Olympus Corpo-
ration, Tokyo, Japan).
Macroautophagy and proteasome inhibition
Alpha-synuclein expression was induced for 48 h by doxycycline
addition (0.1 g/ml or 1 g/ml), and then the autophagy inhibitor
3-methyladenine (3-MA) 10 mM (Sigma Aldrich Co.) or the pro-
teasome inhibitor MG132 10 M (Sigma Aldrich Co.) was added
o the medium for further 18 h. Cell viability was then assessed by
TT assay and cell protein lysates were collected for Western
lotting.
Antibodies
The following primary antibodies were used to run immunoblotting
or immunocytochemistry: anti -syn monoclonal antibody (dilution
1:2500) (Transduction Laboratories, Lexington, KY, USA); anti
-tubulin monoclonal antibody (dilution 1:5000) (Abcam, Cam-
ridge, UK); anti LC3 polyclonal antibody (dilution 1:200) (Abcam,
ambridge, UK); anti-oligomer (A11) polyclonal antibody (dilution
:250) (Invitrogen).
RESULTS
Modulation of -synuclein expression in PC12/TetOn
cells
Fig. 1A shows a Western blotting analysis assessing -syn
xpression in PC12/TetOn cells. Cells were exposed for
6 h to increasing doxycycline concentration. We found a
ositive correlation between doxycycline amount and pro-
ein expression level. In PC12/TetOn cells transfected by
n empty pBI-G vector, the basal level of -syn was neg-
ligible and was not affected by doxycycline addition (data
not shown). We further confirmed -syn-inducible expres-
ion by immunocytochemistry (Fig. 1B). PC12/TetOn cells
y of human -syn expression (WT or A30P) in PC12/TetOn cells. The
e (doxy), while the lower picture shows -syn immunoreactivity after
). Alpha-syn expression at higher magnification (40) before and after
) Western blot showing -syn(WT) and (A30P) cellular bioavailabilitychemistr
xycyclin
10 m
5 m). (Cindependent Western blot assays.
S. Batelli et al. / Neuroscience 195 (2011) 128–137 131Fig. 2. Neuroprotective effect of human -syn against oxidative stress without cellular toxicity. PC12/TetOn cells were seeded in 96-well plates at
100103 cells/well and grown overnight. Next day, cells were exposed to doxycycline 0.1 g/ml or 1 g/ml for 48 h. Afterward, H2O2 150 M was
added for further 72 h and then cell viability was assessed by MTT or cells were fixed with 4% PFA and stained with 0.05% thioflavin-T as described
in methods. (A) Viability of PC12/TetOn cells expressing different levels of human -syn(WT) challenged by H2O2; (B) Viability assay of PC12/TetOn
mbar2.5 m). (J–L) Same situation as in (D–F) (60 magnification; bar2.5 m).
S. Batelli et al. / Neuroscience 195 (2011) 128–137132expressing -syn(WT) after addition of doxycycline 1 g/ml for increasing time intervals; (C) Evaluation of viability of PC12/TetOn expressing different
levels of human -syn(A30P) after oxidative challenge by H2O2. (D) Viability of PC12/TetOn stimulated with doxycycline 1 g/ml to express human
-syn(A30P) for increasing time intervals. *P0.05; **P0.01, one-way ANOVA followed by Tukey’s post-hoc test. (E) Absence of -syn aggregate
formation assessed by thioflavin-T staining in PC12/TetOn cells after 48 h stimulation with doxycycline 1 g/ml. The upper pictures show the basal
condition (doxy), while the doxy conditions are the stimulated cells. (F) Representative dot blot assessing A11 reactivity in uninduced (doxy) and
induced (doxy) condition for both cell lines at two different time-points (48 and 96 h) from doxycycline addition. For interpretation of the referencesFig. 3. Macroautophagy activation after doxycycline addition and -syn expression in PC12/TetOn cells. Cells were seeded at 50103 cell/well in a
ultiwell chamber slide and grown overnight. The next day, doxycycline was added (1 g/ml) for 48 h and then macroautophagic organelle formation
was monitored by LC3-II immunoreactivity (highlighted by arrows), while nuclei were stained by Hoechst 33342. As positive control (CT),
PC12/TetOn mock-transfected with empty pBI-G vector were seeded as previously described but then were kept for 18 h in a starving condition (serum
deprivation[SD]). (A–C) Control condition showing LC3-II immunoreactivity in uninduced PC12/TetOn cells (doxy) or in PC12/TetOn mock
transfected cells cultured in presence of complete medium (CM). Bar10 m (magnification 20). (D–F) LC3-II immunoreactivity as above but after 48 h
induction by doxycycline (doxy) or 18 h SD. Bar10 m (magnification 20). (G–I) Control condition as in (A–C) but at higher magnification (60;to color in this figure legend, the reader is referred to the Web version of this article.
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S. Batelli et al. / Neuroscience 195 (2011) 128–137 133Fig. 4. Inhibition of macroautophagy by 3-MA leads to -syn(WT) accumulation, toxicity, and oligomer formation in PC12/TetOn. (A) PC12/TetOn cells
xpressing -syn(WT) were exposed to 0.1 or 1 g/ml of doxycycline for 48 h, and then the UPS inhibitor MG132 or the macroautophagy inhibitor 3-MA
as added for further 18 h. Alpha-syn(WT) expression level was then quantified by Western blotting, using -tubulin as internal standard. The blot
uantification (three replicates for each condition) is shown in (B). **: P0.01, one-way ANOVA followed by Tukey’s post-hoc test. (C) The same
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S. Batelli et al. / Neuroscience 195 (2011) 128–137134were exposed to 1 g/ml doxycycline for 48 h, and then
-syn immunoreactivity was assessed. We were able to
etect a cytoplasmic increase of the protein (both WT and
30P).
Finally, we verified the cellular presence of -syn over
time (Fig. 1C). Alpha-syn expression was induced with 1
g/ml doxycycline for increasing time intervals (0–96 h).
he protein level doubled 48 h after doxycycline addition,
nd after 96 h, it reached a strong level of expression in
omparison with the basal condition both for the WT and
he A30P form.
ffect of -syn expression level on oxidative stress
response and cellular viability
We have previously shown that low amounts of -syn are
protective against oxidative stress in vitro (Albani et al.,
2004). In order to confirm this point with an independent
model, we decided to challenge PC12/TetOn cells with
hydrogen peroxide (H2O2) for 72 h while we were inducing
-syn expression with low amount of doxycycline (0.1 g/
l). Our results are shown in Fig. 2A, C. The oxidative
reatment was toxic to uninduced cells, with a reduction of
iability of about 50% in comparison with control. On the
ontrary, when we exposed PC12/TetOn to doxycycline
.1 g/ml before oxidative challenge, a significant increase
of cell viability was assessed. In this situation, no differ-
ence was detectable between -syn(WT) and (A30P).
When we treated mock-transfected PC12/TetOn cells with
hydrogen peroxide (H2O2), no protection from H2O2 toxic-
ity was detectable (data not shown).
We have also verified cell viability after -syn overex-
pression induced by doxycycline 0.1 g/ml in absence of
H2O2 by MTT and LDH release assays. At the same time,
-syn aggregation was checked by -syn immunostaining
r A11 anti-oligomer antibody reactivity. We did not find
ny toxic effect or evidence of -syn aggregation, both for
the WT and the A30P form (data not shown).
The further step was to evaluate our model when we
strongly induced -syn expression level. In this situation,
e expected to find -syn toxicity and aggregation, with
oss of neuroprotection against oxidative stress. At first, we
dded to PC12/TetOn growth medium 1 g/ml doxycycline
for increasing time intervals (0–96 h) and then we quanti-
fied cellular viability by MTT assay. As shown in Fig. 2B, D,
no toxicity was recorded even at 96 h, and this situation
was the same for the WT and the mutated form. We have
also increased the induction time with doxycycline 1 g/ml
up to 7 days, without any toxicity (data not shown). When
exposed to doxycycline at 1 g/ml, cells expressing
experiment was carried out using PC12/TetOn overexpressing -syn
nalysis (three replicates for each condition). **: P0.01, one-way A
C12/TetOn cells expressing -syn(WT). The experimental scheme w
by Tukey’s post-hoc test. (F) Cell viability assay for PC12/TetOn cells
carried out as detailed in (A); *: P0.05, one-way ANOVA followed by
treatment on -syn oligomer formation detected by A11 antibody. PC12
0 mM was added for further 18 h. Oligomeric species formation wa
uantification of three independent replicates, performed by normalizininterpretation of the references to color in this figure legend, the reader is refe-syn(WT) were still able to counteract oxidative stress,
hile cells carrying the mutated form were not different
rom control (Fig. 2A, C). To investigate the formation of
-syn aggregates in this situation of high -syn expression
evel, we stained cells with thioflavin-T, but no difference
etween control and induced cells came to light (Fig. 2E).
inally, to assess whether at least -syn oligomers were
accumulating, we performed an A11 antibody assay at
increasing time points (48–96 h). We did not find any
positivity (Fig. 2F).
Macroautophagy and proteasome inhibition in PC12/
TetOn cells
As in our model we did not find evidence of -syn aggre-
ation, we hypothesized that -syn was efficiently re-
moved from the cytosol. To test this, we considered the
involvement of the macroautophagy system and the ubiq-
uitin-proteasome system (UPS), two pathways responsible
for proteins, protein aggregates, or organelles degradation
and recycling. We have verified that macroautophagy and
the proteasome were functions of our cell model and were
inhibited by 3-MA and MG132, respectively (data not
shown).
Alpha-synuclein expression was induced by doxycy-
cline (1 g/ml) for 48 h in both WT and A30P transfected
ells, and then we evaluated macroautophagy activation
y LC3-II immunocytochemistry (Fig. 3). As positive con-
rol (CT), we cultured mock-transfected PC12/TetOn
ells for 18 h in absence of serum to induce starvation. We
oticed macroautophagy activation, with the appearance
f LC3-II-positive spots in serum-starved and doxycycline-
nduced cells, with a stronger reactivity for the -syn(WT)
orm in comparison with the mutated A30P. We have also
hecked whether macroautophagy was activated by the
ddition of doxycycline 0.1 g/ml for 48 h, but no positive
LC3-II reactivity was found (data not shown).
Then, we decided to block macroautophagy (3-MA 10
mM for 18 h) or the UPS (MG132 10 M for 18 h) and
assess -syn accumulation and cellular viability in pres-
ence of doxycycline (0.1 or 1 g/ml). The results are
hown in (Fig. 4). In PC12/TetOn cells expressing
-syn(WT), the inhibition of macroautophagy, but not the
roteasome, led to an accumulation of the protein (Fig. 4A,
). As for cell viability, we detected an increase of cell
oxicity in cells incubated with 3-MA only, and the effect
as stronger at doxycycline 1 g/ml (Fig. 4E). On the other
hand, in PC12/TetOn cells expressing the mutated A30P,
both 3-MA and MG132 induced protein accumulation but
The graph shown in (D) reports the quantification by densitometric
llowed by Tukey’s post-hoc test. (E) Cell viability assessment for the
me described in (A). *: P0.05; **P0.01, one-way ANOVA followed
iong -syn(A30P) after doxycycline stimulation. The experiment was
post-hoc test. (G) Representative dot blot showing the effect of 3-MA
ells were incubated with doxycycline (1 g/ml) for 48 h, and then 3-MA
ed by A11 reactivity. The bar graph in (H) shows the densitometric
signal to -tubulin immunoreactivity in the same blot (not shown). For(A30P).
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S. Batelli et al. / Neuroscience 195 (2011) 128–137 135to a smaller extent than in the WT line (Fig. 4C, D) with a
weak decrease of cell viability at doxycycline 1 g/ml only.
Provided that with the 3-MA treatment -syn(WT)
showed a marked toxic phenotype, we investigated in this
scenario the appearance of -syn aggregates or oligo-
eric species. After the treatment with doxycycline 1 g/ml
and 3-MA, thioflavin-T staining did not show evidence of
insoluble -syn(WT) fibrils (data not shown), whereas we
noticed an increase of oligomers detected by A11 anti-
body. In -syn(A30P) expressing cells, we did not find A11
eactivity following the previously described experimental
cheme (Fig. 4G, H).
DISCUSSION
Even if -syn aggregation is considered of relevance for
PD pathogenic process, the molecular mechanism trigger-
ing PD starting from -syn homeostasis alteration is still a
matter of debate.
Here, we describe a tightly controllable cellular model
of -syn expression that allowed us to finely tune -syn
ntracellular level and find out how the protein concentra-
ion affects its function and/or toxicity. Moreover, we com-
ared the familial PD-linked mutation A30P with the wild
ype form of the protein. When -syn was expressed at low
level, we confirmed a neuroprotective role against oxida-
tive stress, as we have already demonstrated in a different
cellular model (Albani et al., 2004). This -syn-mediated
protective function is to be underlined, as oxidative stress
is a main feature of PD and neurodegeneration in general,
so a loss of this -syn positive action, for instance as a
onsequence of its sequestration into LB, might contribute
o PD onset. Alpha-syn neuroprotective action was inde-
endent from the presence of the mutation A30P, suggest-
ng that this amino acidic substitution does not map within
he protein domain required for neuroprotection, probably
he C-terminal part that is also involved in other trophic
unctions of -syn, like the proliferation of dopaminergic
cells (Albani et al., 2004; Kim et al., 2000, 2002; Park et al.,
2002; Yin et al., 2011). In this condition of low -syn
xpression, we did not notice -syn aggregation (oligom-
rs or fibrils) or toxicity, likely as a critical concentration
hreshold value was not reached. Coherently, with doxy-
ycline 0.1 g/ml no macroautophagy activation was
found.
When we tried to induce in PC12/TetOn -syn aggre-
gation by an enhanced level of -syn expression obtained
y the addition of doxycycline 1 g/ml, we did not find any
ggregate or A11 reactivity both for -syn(WT) and
A30P), but in this case the autophagic machinery of the
ells was activated, suggesting that they were starting
rotective pathways to cope with the excess of -syn and
revent aggregate formation. It is of note that, under in-
reased -syn expression, while -syn(WT) was still able
o counteract oxidative stress, the mutated form lost this
unction, raising the possibility that in this situation the
resence of the A30P mutation had some dose-dependent
eleterious effect that nullified the neuroprotective pheno-
ype. On the contrary, the WT form did not aggregate as itas removed, but the amount of soluble -syn molecules
as probably still sufficient to keep the antioxidant
roperty.
As in our model we had evidence of macroautophagy
ctivation after the addition of doxycycline 1 g/ml, we
ried to accumulate -syn by macroautophagy inhibition. In
this situation, -syn(WT) accumulated inside PC12/TetOn
ells, leading to cell death and the formation of oligomers.
his result is in agreement with the literature, where mac-
oautophagy was reported to be crucial for -syn(WT)
degradation in neurons (Vogiatzi et al., 2008; Xilouri et al.,
2008). Moreover, it was also reported that -syn was
ble to inhibit macroautophagy, and probably this
trongly contributes to its accumulation with a kind of
ositive loop, considering that macroautophagy is acti-
ated for -syn removal (Winslow et al., 2010). Protea-
some inhibition in PC12/TetOn had no effect on -syn(WT)
ccumulation and toxicity, suggesting a minor role for the
roteasome in degrading -syn(WT) in our model. In our
xperimental setting, -syn(A30P) was removed by the
ells even in presence of macroautophagy inhibition, and
n fact the -syn(A30P) form did not show toxicity and
ligomer formation after 3-MA treatment, even if its con-
entration was slightly increased, but probably to an extent
ot sufficient to produce a detectable amount of aggre-
ated forms. Clearly, in the case of -syn(A30P) other
ellular degrading pathways are involved, as we dem-
nstrated by proteasome inhibition that increased
-syn(A30P) accumulation, even if also in this case the
raction of -syn(A30P) that was not degraded was lim-
ited and unable to have strong toxic effects. We can
speculate that in PC12/TetOn cells -syn(A30P) expres-
sion at high level started multiple degrading pathways,
including autophagy and the proteasome, maybe for a
more toxic phenotype of the molecule in comparison
with the WT, a point in agreement with the loss of viability
protection against oxidative stress in the case of -syn(A30P)
only. Consequently, to find aggregation and toxicity of
-syn(A30P) in our model, it is likely that both macroau-
ophagy and the proteasome should be inhibited at the
ame time. We have attempted to perform this protocol,
ut unfortunately the double treatment was too toxic for
ells. Of course, we do not rule out that in our PC12/
etOn -syn(A30P) may be partly degraded also by
ther autophagic pathways like the chaperone-mediated
utophagy (CMA), as already reported (Xilouri et al.,
009; Yang et al., 2009).
In conclusion, our results confirmed a neuroprotective
ole of -syn at low level of expression against oxidative
stress independently from the presence of a pathogenetic
mutation and explain why our PC12/TetOn cells overex-
pressing -syn(WT) or (A30P) did not show any reduction
in cell viability, as they are able to efficiently cope with
-syn overproduction by activating degrading mecha-
isms, including macroautophagy and the proteasome.
owever, -syn(WT) and (A30P) follow different pathways
of removal with a stronger involvement of macroautophagy
for the WT form, while the mutant A30P elicited multiple
degrading pathways (Fig. 5).
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